Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

被引：65

作者：

Kataja, V. ^{[1
]}

Castiglione, M. ^{[2
]}

机构：

[1] Vaasa & Kuopio Univ, Dept Oncol, Vaasa Cent Hosp, Kuopio, Finland

[2] Univ Geneva, Inst Social & Prevent Med, Geneva, Switzerland

来源：

ANNALS OF ONCOLOGY | 2009年 / 20卷

关键词：

ADJUVANT CHEMOTHERAPY; BONE LOSS; TRASTUZUMAB; TAMOXIFEN; CONSENSUS; THERAPY; TRIAL; WOMEN;

D O I：

10.1093/annonc/mdp114

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：10 / 14

页数：5

共 17 条

[1]

Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0

[2]

[Anonymous], NCCN Clinical Practice Guidelines in Oncology - Breast Cancer

[3]

COOMBES RC, 2004, NEW ENGL J MED, V351, P2641

[4] Estimates of the cancer incidence and mortality in Europe in 2006 [J].

Ferlay, J. ;

Autier, P. ;

Boniol, M. ;

Heanue, M. ;

Colombet, M. ;

Boyle, P. .

ANNALS OF ONCOLOGY, 2007, 18 (03) :581-592

[5] Progress and promise:: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 [J].

Goldhirsch, A. ;

Wood, W. C. ;

Gelber, R. D. ;

Coates, A. S. ;

Thuerlimann, B. ;

Senn, H.-J. ;

Members, Panel .

ANNALS OF ONCOLOGY, 2007, 18 (07) :1133-1144

[6] Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCICCTG MA.17 [J].

Goss, PE ;

Ingle, JN ;

Martino, S ;

Robert, NJ ;

Muss, HB ;

Piccart, MJ ;

Castiglione, M ;

Tu, DS ;

Shepherd, LE ;

Pritchard, KI ;

Livingston, RB ;

Davidson, NE ;

Norton, L ;

Perez, EA ;

Abrams, JS ;

Cameron, DA ;

Palmer, MJ ;

Pater, JL .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (17) :1262-1271

[7] Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer [J].

Hershman, Dawn L. ;

McMahon, Donald J. ;

Crew, Katherine D. ;

Cremers, Serge ;

Irani, Dinaz ;

Cucchiara, Gina ;

Brafman, Lois ;

Shane, Elizabeth .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (29) :4739-4745

[8] Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer [J].

Howell, A ;

Cuzick, J ;

Baum, M ;

Buzdar, A ;

Dowsett, M ;

Forbes, JF ;

Hoctin-Boes, G ;

Houghton, I ;

Locker, GY ;

Tobias, JS .

LANCET, 2005, 365 (9453) :60-62

[9]

HUGHES L, 2006, SAN ANT BREAST CANC

[10] Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial [J].

Jakesz, R ;

Jonat, W ;

Gnant, M ;

Mittlboeck, M ;

Greil, R ;

Tausch, C ;

Hilfrich, J ;

Kwasny, W ;

Menzel, C ;

Samonigg, H ;

Seifert, M ;

Gademann, G ;

Kaufmann, M .

LANCET, 2005, 366 (9484) :455-462

← 1 2 →